HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.

In responding patients HS1 variations before and after therapy, measured with a Paired Student’s t -test, was highly significant (western blotting p = 0.002 and Real-Time PCR p = 0.001) while in non responding patients the variation before and after therapy was significant only in Real-Time PCR (p = 0.024, western blotting p = 0.067) probably because of the little number of non responding patients.

also in 132,142 other papers